It has also been reported that HSP90 inhibitors seem to have contradictory effects depending on the molecular subtype of CRC (CMS) [81], demonstrating a need for prior identification of patient CMS to improve the effectiveness of HSP90 inhibitors when combined with different administered chemotherapies. This evidence concerns the gene HSP90AB1 and colorectal carcinoma.